Expanded Access Policy
TG Therapeutics is committed to bringing our investigational therapies to patients as fast as possible. We believe the best way for patients to access our investigational therapies is through participation in clinical trials, with the goal of obtaining regulatory approval of our products and allowing access to the broadest group of patients possible.
At this time, TG Therapeutics does not have a program to provide its investigational therapies to patients on an expanded access basis pursuant to section 561(b) of the U.S. Federal Food, Drug, and Cosmetic Act (FDCA). Because we do not currently have an expanded access program, we have not yet established procedures for making such requests or criteria for evaluating them. TG Therapeutics will update this Policy if the company decides to make its investigational therapies available on an expanded access basis.
For questions or additional information about this Policy, please contact clinicalsupport@tgtxinc.com. We are committed to responding to inquiries within five (5) business days of receipt.
Patients may be able to access TG Therapeutics investigational therapies by participating in ongoing clinical trials. Whether or not a patient is eligible to enroll in any of our trials depends on a number of factors, including the specific requirements of each trial and the status of that trial. For more information about our trials, please visit Our Trials Overview or Clinicaltrials.gov – TG Trials.